Technology ID

Base-Covered HIV-1 Envelope Ectodomains and Their Use

Lead Inventor
Kwong, Peter (NIAID)
Mascola, John (NIAID)
Zhou, Tongqing (NIAID)
Olia, Adam (NIAID)
Rawi, Reda (NIAID)
Yang, Yongping (NIAID)
Cheng, Cheng (NIAID)
Development Stages
Pre-clinical (in vivo)
Development Status
Animal Studies

Researchers at the Vaccine Research Center (“VRC”) of the National Institute of Allergy and Infectious Diseases (“NAID”) continue to pursue a safe and effective HIV-1 vaccine to combat the HIV-1/AIDS pandemic. 

       To this end, researchers have engineered the soluble HIV-1 ectodomain trimer so that it is stabilized in its prefusion conformation by artificial disulfides, helix-disrupting prolines, and other structure-based alterations.  However, mice and non-human primates immunized with these engineered soluble HIV-1 trimers produced a significant (>90% in some cases) immune response to the exposed trimer base.

      VRC researchers further modified the engineered prefusion soluble HIV-1 trimers by adding N-linked glycans to specific sites on the protein’s base to block this immunodominant surface.  They found that these N-linked glycans did reduce production of non-neutralizing antibodies directed to the trimer base.  These soluble, glycan-masked prefusion HIV-1 trimers are envisioned as being a part of a heterologous prime-boost vaccine regimen.

       This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as further development and evaluation under a research collaboration.

Commercial Applications
  • Vaccine for prevention of HIV-1 infection
  • Therapeutic vaccine for treatment of HIV-1 infection

  • Competitive Advantages
    Currently, no licensed HIV vaccine exists
    Licensing Contact:
    Petrik, Amy
    Phone: 301-827-0255